An estimated 30 million to 50 million doses of Johnson & Johnson's COVID-19 vaccine made early this year sits idle in Emergent BioSolutions’ plant in Baltimore, awaiting a green light from U.S. regulators to ship, sources told Reuters.
#Johnson&Johnson #vaccine #News #Reuters #COVID19 #EmergentBioSolutions
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
#Johnson&Johnson #vaccine #News #Reuters #COVID19 #EmergentBioSolutions
Subscribe: http://smarturl.it/reuterssubscribe
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en
Sign in or sign up to post comments.
Be the first to comment